Clinical Trial: Buparlisib (BKM120) In Patients With Recurrent/Refractory Primary Central Nervous System Lymphoma (PCNSL) and Recurrent/Refractory Secondary Central Nervous System Lymphoma (SCNSL)

Study Status: Completed
Recruit Status: Completed
Study Type: Interventional

Official Title: A Phase II Trial Of Buparlisib (BKM120) In Patients With Recurrent/Refractory Primary Central Nervous System Lymphoma (PCNSL) and Recurrent/Refractory Secondary Central Ne

Brief Summary: The purpose of this study is to find out what effects, good and/or bad, Buparlisib (also known as BKM120) has on lymphoma and the central nervous system.

Detailed Summary:
Sponsor: Memorial Sloan Kettering Cancer Center

Current Primary Outcome: progression free survival [ Time Frame: up to 24 weeks ]

Progression-free survival (PFS) is defined as the time from the date of treatment start to the date of the first documented PD or death due to any cause. PFS will be based on the investigator's assessment of MRI, CSF studies and clinical presentation.


Original Primary Outcome: Same as current

Current Secondary Outcome: Number of Adverse events that occur [ Time Frame: 2 years ]

Will be summarized based on the Common Toxicity Criteria version 4.0.


Original Secondary Outcome: Same as current

Information By: Memorial Sloan Kettering Cancer Center

Dates:
Date Received: November 21, 2014
Date Started: November 20, 2014
Date Completion:
Last Updated: February 9, 2017
Last Verified: February 2017